Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on X:
“Awaiting the Camizestrant ODAC decision today. Learning that ODAC voting is highly concordant with FDA approval.
‘Approval followed 142 of 147 positive votes for initial approvals (97%)‘. Advisory Committee Votes and US Food and Drug Administration Decisions on Prescription Drugs.”
Title: Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
Authors: C. Joseph Ross Daval, Theodore W. Teng, Massimiliano Russo, Aaron S. Kesselheim
Read The Full Article
Other articles about FDA on OncoDaily.